



Published in final edited form as:

Stroke. 2008 December ; 39(12): 3159–3165. doi:10.1161/STROKEAHA.108.522789.

## Segment-Specific Genetic Effects on Carotid Intima-Media Thickness: The Northern Manhattan Study

Yi-Chu Liao, MD, MS<sup>1,2,5</sup>, Hsiu-Fen Lin, MD<sup>4,6</sup>, Tatjana Rundek, MD, PhD<sup>7</sup>, Rong Cheng, PhD<sup>8</sup>, Yuh-Cherng Guo, MD<sup>2,6</sup>, Ralph L. Sacco, MD, MS<sup>7</sup>, and Suh-Hang Hank Juo, MD, PhD<sup>1,3,4</sup>

1 Graduate Institute of Medical Genetics, Kaohsiung Medical University, Kaohsiung, Taiwan

2 Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

3 Center of Excellence for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

4 Department of Neurology, Kaohsiung Medical University, Kaohsiung, Taiwan

5 Department of Neurology, Taichung Veterans General Hospital, Taichung, Taiwan

6 Department of Neurology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

7 Department of Neurology, Miller School of Medicine, University of Miami, Fla

8 Gertrude H. Sergievsky Center, Columbia University, New York, NY

### Abstract

**Background and Purpose**—Carotid intima-media thickness (IMT) is a surrogate marker of subclinical atherosclerosis and a strong predictor of stroke and myocardial infarction. The object of this study was to determine the association between carotid IMT and 702 single nucleotide polymorphisms in 145 genes.

**Methods**—B-mode carotid ultrasound was performed among 408 Hispanics from the Northern Manhattan Study. The common carotid artery IMT and bifurcation IMT were phenotypes of interest. Genetic effects were evaluated by the multivariate regression model adjusting for traditional vascular risk factors. For each individual, we calculated a gene risk score (GRS) defined as the total number of the significant single nucleotide polymorphisms in different genes. Subjects were then divided into 3 GRS categories using the 2 cutoff points: mean GRS  $\pm 1$  SD.

**Results**—We identified 6 significant single nucleotide polymorphisms in 6 genes for common carotid artery IMT and 7 single nucleotide polymorphisms in 7 genes for bifurcation IMT using the probability value of 0.005 as the significant level. There were no common significant genes for both phenotypes. The most significant genes were the tissue plasminogen activator ( $P=0.0005$  for common carotid artery IMT) and matrix metalloproteinase-12 genes ( $P=0.0004$  for bifurcation IMT). Haplotype analysis did not yield a more significant result. Subjects with GRS  $\geq 9$  had significantly increased IMT than those with GRS  $\leq 5$  ( $P<0.001$ ). GRS was an independent predictor of both common carotid artery IMT ( $P=2.3 \times 10^{-9}$ ) and bifurcation MT ( $P=7.2 \times 10^{-8}$ ).

Correspondence to Suh-Hang Hank Juo, MD, PhD, Kaohsiung Medical University, 100 TzYou First Road, Kaohsiung City 807, Taiwan. E-mail E-mail: hjuo@kmu.edu.tw.

#### Disclosures

None.

**Conclusions**—Multiple genes contributed to the variation in carotid IMT. IMT in different carotid segments may be regulated by different sets of susceptibility genes.

### Keywords

atherosclerosis; carotid intima-media thickness; genetics; polymorphism

Stroke is a multifactorial disease and genetic factors contribute to its pathogenesis. Measurement of carotid intima-media thickness (IMT) is a well-established surrogate marker of subclinical atherosclerosis and is associated with increased risk of stroke and cardiovascular disease.<sup>1</sup> Family studies have demonstrated appreciable heritability of IMT,<sup>2</sup> which warrants identification of susceptibility genes to the phenotypic variation in IMT. Previous studies investigating a limited number of candidate genes in association with subclinical atherosclerosis have reported some promising quantitative trait loci.<sup>3</sup> Due to the advance of genotyping technologies, it is now possible to genotype a large number of single nucleotide polymorphisms (SNPs) by high-throughput platforms. These new technologies provide a unique opportunity to conduct more comprehensive genetic association studies by exploring a large number of candidate genes and to yield better insight to the complex pathogenesis of atherosclerosis.

There is no consensus on which carotid arterial site can serve as a better proxy of clinical cardiovascular outcomes. Each segment of carotid artery has its own unique anatomy and hemodynamic environment and therefore is prone to different pathophysiological mechanisms. It has been suggested that the intimal thickening in the common carotid artery (CCA) is more representative of the total body atherosclerosis burden, whereas the IMT in the internal carotid artery (ICA) represents primarily a focal atherosclerotic process in response to the local turbulent flow.<sup>4</sup> Because both the traditional cardiovascular risk factors and hemodynamic surroundings have differential influences on the CCA, carotid bulb, and ICA,<sup>5</sup> the proatherosclerotic genes may have various contributions to different carotid segments.

To explore the genetic determinants of carotid atherosclerosis, we selected 145 candidate genes involved in pathophysiology of atherosclerosis. They included genes associated with the extracellular matrix remodeling, hemostasis, endothelium function, renin-angiotensin system, inflammation, antioxidation, and glucose and lipid metabolism. We investigated the relationships between SNPs in these candidate genes and carotid segment-specific IMT among a Caribbean-Hispanic population from the North Manhattan Study (NOMAS). In addition to a single gene effect, we also evaluated the combined effect of multiple genes on carotid IMT.

## Materials and Methods

### Study Population

The study subjects were drawn from the prospective community-based NOMAS cohort (53.1% Hispanics, 23.7% blacks, 20.1% whites, 3.1% others).<sup>6</sup> Four hundred eight subjects fulfilling the following criteria were enrolled in the present study: (1) self-identification to be of Hispanic/Spanish origin through a series of interview questions modeled after the US census; (2) carotid ultrasound performed; and (3) DNA sample available for genetic studies. Our Hispanic population consisted of 62% Dominicans, 13% Puerto Ricans, 11% Cubans, and 14% other Hispanics.<sup>7</sup> Vascular risk factors, including body mass index, body weight, smoking history, diabetes, and hypertension,<sup>7</sup> were inquired and fasting blood samples were analyzed for blood sugar, high-(HDL-C) and low-density lipoprotein cholesterol, total cholesterol, and triglycerides. The study was approved by the Columbia University Medical Center Institutional Review Board.

## Intima-Media Thickness Measurement

Carotid IMT was assessed by high-resolution B-mode ultrasound (Diasonics 2D-Gateway) with modification from the Atherosclerosis Risk in Communities protocol.<sup>8</sup> The IMT scanning consists of the near and far wall of CCA, carotid bifurcation (Bif), and ICA in the plaque-free area.<sup>8</sup> Measurements were performed by the M' Ath automatic computerized edge tracking systems (Canevas).<sup>9</sup> Our interreader and intrareader correlation coefficients were 0.77 and 0.94, respectively.

## Genes and Single Nucleotide Polymorphism Selection

One hundred forty-five candidate genes with functional relevance to atherosclerosis were selected (Supplemental Table I, available online at <http://stroke.ahajournals.org>). The candidate SNPs were selected according to the following criteria: (1) SNPs leading to amino acid changes; (2) SNPs have been examined in previous studies; (3) SNPs located at evolutionarily conserved sequence homology (<http://genome.lbl.gov/vista/index.shtml>); (4) tagging SNPs across different human populations (<http://pga.gs.washington.edu>); and (5) functional SNPs. Any eligible SNP needs to have a minor allele frequency >0.05 and been submitted to the dbSNP database by more than one source. In addition, to reduce SNP loci that can be tagged by each other, an attempt was made to select SNPs with a distance of more than 3000 base pairs. SNP genotyping was performed using the GoldenGate Assay (Illumina Inc, San Diego, Calif).<sup>10</sup> The final set consisted of 702 SNPs that covered a genomic region of 6.7 Mb. The average and median number of candidate SNPs at each gene were 4.8 and 4 (range, 3 to 15), respectively.

## Statistical Analysis

Statistical analysis was performed by SAS 9.0 software (SAS Institute Inc, Cary, NC). Hardy-Weinberg equilibrium was computed by a  $\chi^2$  goodness-of-fit test. A probability value of 0.01 was used as an indication of deviation from Hardy-Weinberg equilibrium because of a large number of SNPs ( $n=702$ ) tested. Thirty-six SNPs were not in Hardy-Weinberg equilibrium and were excluded from the subsequent analysis. According to our previous heritability results, IMT in the ICA was under weaker genetic influences than in the carotid bifurcation or in the CCA.<sup>11</sup> Therefore, the present study only focused on IMT in the CCA (CCA\_IMT) and in the Bif (Bif\_IMT).

Clinical parameters (age, sex, body mass index, body weight, smoking, diabetes, hypertension, serum level of total cholesterol, low-density lipoprotein cholesterol, HDL-C, triglycerides) were assessed by univariate regression to determine significant predictors of IMT. Pearson correlation was used to determine the relationships between IMT in any 2 of the 3 segments. Associations between SNPs and IMT were evaluated by multivariate regression after adjusting for significant covariates. We used 3 models (assuming the rare allele had an additive, dominant, or recessive effect) to evaluate the genetic effects on IMT. A threshold of  $P<0.005$  was used as a cutoff level of significance. Significant SNPs were considered in the subsequent analyses of combined genetic effects and in the analyses of the gene-gene interactions by including interaction terms in the regression models. Haploview software was used to define haplotype blocks of each gene<sup>12</sup> and the Hap-Clustering program for the haplotype analysis.<sup>13</sup>

For each individual, we computed a gene risk score (GRS) defined as the total number of the independent risk SNPs that were associated with Bif\_IMT or CCA\_IMT at the significant level of 0.005. For a gene having more than one significant SNP, we used regression analysis to identify their independency of contribution to IMT variation. The contribution of GRS to the IMT variance was assessed using a regression model adjusting for significant covariates. We performed bootstrap permutation to estimate the precision of test statistics obtained from GRS.

The null distribution of the test statistics was generated by randomly taking 13 genes out of the 145 genes and using the most significant SNP in each gene to calculate a simulated GRS. Multivariate regression analysis was performed to evaluate the associations between simulated GRS and IMT. The empirical probability values are calculated as  $(R+1)/(N+1)$  where  $R$  is the number of times the permuted test yielded a probability value less than the observed probability value and  $N$  is the number of iterations in the permutation test. Subjects were then divided into 3 GRS categories using the 2 cutoff points: mean GRS  $-1$  SD and mean GRS  $+1$  SD. The adjusted CCA\_IMT and Bif\_IMT in the 3 GRS categories were compared by analysis of variance and a post hoc pairwise test using the Scheffe correction.

## Results

Clinical characteristics for the 408 participants are presented in Table 1. The mean age was 64.5 years (range, 50 to 91 years); 45% were men. The average IMT (mm) was  $0.91 \pm 0.09$  in CCA,  $0.92 \pm 0.09$  in the Bif, and  $0.83 \pm 0.07$  in ICA. The CCA\_IMT and Bif\_IMT were moderately correlated (Pearson correlation coefficient = 0.46,  $P < 0.001$ ), and the correlation coefficients between ICA\_IMT and the 2 other measurements were 0.43 (Bif\_IMT) and 0.37 (CCA\_IMT), respectively ( $P < 0.001$ ). In univariate analysis, increased CCA\_IMT was significantly associated with increased age and body weight and hypertension (Table 1). In contrast, increased Bif\_IMT was associated with men and decrease in HDL-C levels.

SNPs in 13 genes were significantly associated with CCA\_IMT or Bif\_IMT after adjusting for age, sex, body weight, hypertension, and HDL-C levels ( $P < 0.005$ ; Table 2). For these 13 “significant” genes, only one SNP of each gene reached the significant level of 0.005. SNPs in 6 genes were found to be predictors of CCA\_IMT. They included the tissue plasminogen activator (*PLAT*), thrombospondin 1 (*THBS1*), nitric oxide synthase 1 (*NOS1*), P-selectin (*SELP*), sodium channel 1  $\beta$  (*SCNN1B*), and chemokine (C-X-C motif) ligand 12 (*CXCL12*) genes. None of the polymorphisms in these genes were associated with Bif\_IMT. SNPs significantly associated with Bif\_IMT were in the following genes: matrix metalloproteinase 12 and 3 (*MMP12* and *MMP3*), transforming growth factor  $\beta 2$  (*TGF $\beta$ 2*), angiotensin I converting enzyme (*ACE*), prostaglandin-endoperoxide synthase 2 (*PTGS2*, aka cyclooxygenase-2 [*COX-2*]), renin (*REN*), and paraoxonase 1 (*PON1*). We did not find any significant gene–gene interactions among these significant genes for either CCA\_IMT or Bif\_IMT. For haplotype analysis, we found that rs6658835–rs12097734 in *TGF $\beta$ 2* had the most significant haplotype specific probability value of 0.0021 for Bif\_IMT (Supplemental Table II). Seven genes (*PON1*, *CXCL12*, *ACE*, *SCNN1B*, *SELP*, *MMP3*, and *THBS1*) yielded haplotype-specific probability values between 0.0052 and 0.0466. *PTGS2*, *REN*, *NOS1*, *MMP12*, and *PLAT* genes did not show any significant results (all probability values  $> 0.05$ ) for either CCA\_IMT or Bif\_IMT.

The average GRS was  $6.9 \pm 1.7$  (range, 0 to 12). In the multivariate regression model, a higher GRS was significantly associated with increased CCA\_IMT and Bif\_IMT ( $P = 2.3 \times 10^{-9}$  and  $7.2 \times 10^{-8}$ , respectively; Table 3). The empirical probability value in 500 000 permutations was  $2 \times 10^{-6}$  for both CCA\_IMT and Bif\_IMT. The GRS explained a greater proportion of IMT variation than other covariates ( $r^2_{\text{gene}}$  versus  $r^2_{\text{covariate}}$  = 8.9% versus 7.5% for CCA\_IMT; 7.2% versus 4.1% for Bif\_IMT). For CCA\_IMT, the effect size of the GRS was comparable to an effect of a 5-year increment in age ( $\beta = 0.015$  per 1-U increase in GRS;  $\beta = 0.014$  per 5-year increase in age).

Based on the 2 GRS cutoff points, subjects were then divided into low- (0 to 5), intermediate- (6 to 8), and high-risk (9 to 12) groups. A dose–response relationship was observed between IMT and the 3 GRS categories (Figure). The average CCA\_IMT in the low-, intermediate-, and high-risk groups were  $0.87 \pm 0.08$ ,  $0.91 \pm 0.08$ , and  $0.94 \pm 0.09$  mm, and average Bif\_IMT

were  $0.90\pm 0.07$ ,  $0.92\pm 0.08$ , and  $0.96\pm 0.13$  mm, respectively. The high-risk GRS group had significantly higher CCA\_IMT and Bif\_IMT than the low-risk group ( $P<0.001$ ).

## Discussion

We found SNPs in 13 candidate genes associated with carotid IMT in a Hispanic population. These genes are involved in hemostasis (*PLAT*, *THBS1*), extracellular matrix remodeling (*MMP3*, *MMP12*, *TGFB2*), inflammation (*CXCL12*, *PTGS2*), antioxidation (*PON1*), endothelium function (*NOS1*, *SELP*), and the renin–angiotensin system (*SCNNIB*, *ACE*, *REN*). A cumulative effect of these genes explained a significant variation in carotid IMT. Subjects with multiple risk genotypes (ie, high GRS) had significantly increased IMT. The effects of genetic and vascular risk factors varied between carotid artery segments, which was most likely due to different anatomy, hemodynamics, and pathogenic mechanisms of atherosclerosis.

Six SNPs were significantly associated with CCA\_IMT, which are located in the *PLAT*, *THBS1*, *NOS1*, *SELP*, *CXCL12*, and *SCNNIB* genes. Elevated serum levels of tissue plasminogen activator (encoded by *PLAT*) have been reported to be associated with worse IMT.<sup>14</sup> Our study is in accordance with the results from the study by de Maat et al,<sup>15</sup> which showed that polymorphisms in *PLAT* accounted for the IMT variation in the general population. We also found that the nonsynonymous polymorphism rs2292305 (Ala523Thr) in *THBS1* was associated with increased IMT. In a large study of 2850 subjects, the *THBS1* Ans700Ser polymorphism was a significant risk factor for myocardial infarction.<sup>16</sup> Because thrombospondin-1 (encoded by *THBS1*) can enhance vascular smooth muscle cell proliferation and adhesion molecules expression,<sup>17,18</sup> it could accelerate the atherosclerotic process in carotid and coronary arteries.

*SELP* and *CXCL12* may initiate the atherosclerosis cascade in CCA\_IMT. P-selectin (encoded by *SELP*) may recruit the monocytes to injured endothelium, and the stromal cell-derived cell factor (encoded by *CXCL12*) may further trigger the monocyte differentiation toward macrophage.<sup>19</sup> Our results showed that both genes conferred susceptibility to carotid atherosclerosis. In concert with our findings, Koyama et al demonstrated a positive correlation between the expression level of P-selectin and carotid IMT.<sup>20</sup> The association between *CXCL12* polymorphisms and IMT also has been reported by Coll et al in HIV-infected patients.<sup>21</sup> Although the other 2 significant genes (*SCNNIB* and *NOS1*) in our study have not been frequently investigated in IMT, plenty of evidence is available to support their genetic effects on atherosclerosis. For example, the neuronal nitric oxide synthase (encoded by *NOS1*) could suppress neointimal formation in mouse carotid arteries,<sup>22</sup> and polymorphisms in *SCNNIB* have been implicated in blood pressure regulation<sup>23</sup> and consequently influenced the atherosclerotic process.

Among the 7 genes significantly related to Bif\_IMT in the present study, 4 of them (*ACE*, *PON1*, *PTGS2*, and *MMP3*) have been reported by other investigators. Based on the meta-analysis,<sup>24</sup> the *ACE* Ins/Del polymorphism had significant influence on CCA\_IMT in whites and Asians. In Hispanics, we found a similar effect for Bif\_IMT, although a direct comparison cannot be made because these studies analyzed different genetic polymorphisms. Similar to our findings, the study by Rauramaa et al showed a positive association between the *MMP3* polymorphism and Bif\_IMT.<sup>25</sup> However, a recent study of 1000 subjects reported an association of *MMP3* polymorphism with IMT only among patients with hypertension.<sup>26</sup>

We found the G allele of the nonsynonymous SNP rs662 in *PON1* to be significantly associated with increased IMT. Previous reports on the associations between *PON1* and IMT among whites and blacks have been inconclusive.<sup>27,28</sup> *PON1* exerts an antiatherogenic effect by

protecting low-density lipoprotein cholesterol particles against oxidation. Because the Gln(A) → Arg(G) substitution causes a lower PON1 activity,<sup>29</sup> it partly may have explained the finding that Arg(G) carriers had a higher risk for stroke<sup>30</sup> and possibly increased IMT as shown in this study. We also found that the G allele of *PTGS2* rs20417 (G-765C) had a detrimental effect on IMT. This observation is consistent with the previous reports, in which the G→C substitution resulted in lower transcription efficacy, diminished inflammatory response, lower IMT values, and reduced stroke risk.<sup>31,32</sup>

The 3 significant genes related to Bif\_IMT (*MMP12*, *TGFB2*, and *REN*) in our study have been rarely investigated in the association studies. In transgenic animal models, the overexpression of *MMP12* caused extensive atherosclerosis in the aorta and coronary arteries.<sup>33</sup> The transforming growth factor  $\beta$ 2 encoded by *TGFB2* was shown to stimulate the matrix production and to have a regulatory role in inflammation.<sup>34</sup> We observed a significant association between SNPs in genes associated with renin–angiotensin metabolism (*ACE* and *REN*) and Bif\_IMT. Although renin (encoded by *REN*) regulates the first step of the renin–angiotensin pathway, its association with atherosclerosis has rarely been studied.

Our results suggest that IMT in CCA and IMT in Bif may be controlled by a different set of genes. The genes involved in hemostasis and endothelial function seem to have a greater effect on CCA\_IMT, whereas the genes involved in extracellular matrix remodeling and the renin–angiotensin system may have greater influence on Bif\_IMT. Similar to this finding, the quantitative trait loci of ICA\_IMT and CCA\_IMT was mapped to different genomic regions in the Framingham Heart Study Offspring Study.<sup>35</sup> Different anatomic and hemodynamic features in CCA and Bif may interact with unique set of genes involved in particular pathogenic pathways of IMT development. It has been shown that laminar flow and oscillatory shear stress trigger diverse endothelium responses and gene expressions.<sup>36,37</sup> In vitro, an increased level of arterial shear stress induces endothelial quiescence and an atheroprotective gene expression profile. Low shear stress, which is prevalent at atherosclerosis-prone sites, stimulates an atherogenic phenotype.<sup>38</sup> These findings suggest that changes in levels of shear stress influence the arterial wall responses from less to more proliferative phenotypes, which may underlie observed differences in genetic effects on CCA IMT and BIF IMT. Information on genetic contributions to the different segments of carotid IMT is limited<sup>2</sup> and needs further research.

We used GRS as a single measure to estimate a cumulative effect of the genes significantly associated with IMT. The GRS accounted for a substantial variance in both CCA\_IMT and Bif\_IMT. In the epidemiological studies, IMT was an independent risk factor for stroke and other vascular diseases even after adjusting for dyslipidemia, diabetes, and other vascular risk factors.<sup>39</sup> Therefore, genetic contributions may provide additional information to the IMT variance and improve the models to predict stroke beyond traditional risk factors. The high-risk group (GRS  $\geq 9$ ) had significantly increased IMT than the low-risk group regardless of the composition of susceptible genes (Figure). Use of the GRS may simplify an assessment of multiple gene effects in complex diseases and may provide a better estimate of individual susceptibility to atherosclerosis.

The present study has several limitations. First, a large number of SNPs tested in this study may raise a concern of inappropriate correction for multiple testing. However, the candidate genes are selected based on a priori hypothesis and they are biologically correlated. A very conservative statistical correction such as Bonferroni's correction would reject most of the biologically important findings in a polygenetic trait like atherosclerosis. Instead of performing permutation test for individual SNPs, we use bootstrap permutation to test the statistical precision of GRS. The highly significant probability values for the GRS have emphasized the contribution of these genes to increased IMT. Our results support that using cumulative effects

from multiple genes is more advantageous in identifying susceptibility genes in complex diseases, especially when the genetic effect of individual gene is expected to be modest. Second, current sample size may restrict our ability to identify gene–gene or gene–environment interactions. We also acknowledge that the sparse spacing of SNPs may attenuate the power to detect a true association in some candidate genes and some of the functional SNPs could not have been genotyped by the Illumina BeadArray technology. Although the present study focuses on a single ethnic group, we cannot exclude the possibility of population substructure in our participants. Finally, some technical issues such as a difference in the reliability of IMT measurements in CCA and Bif may contribute to the different effects of genetic and vascular risk factors between these 2 carotid segments. The reliability of IMT measurements in our laboratory is high<sup>8</sup> and comparable to the results from other large epidemiological studies and therefore less likely influenced our results.

## Summary

This is the first study to screen a large number of susceptibility genes for carotid IMT in a population-based sample of Caribbean Hispanics. We have found 13 candidate genes contributing to the variation of carotid IMT. Several of them (*MMP12*, *SELP*, *NOS1*, *THBS1*, *TGFB2*, *SCNN1B*, and *REN*) have never been reported in association with carotid IMT. Also, we report a cumulative effect of several genes on IMT. Although these findings need to be replicated in different populations, our observation may provide a potential direction for the future gene–IMT association studies. Given the discrepancy between the genetic contributions to CCA\_IMT and Bif\_IMT, we believe that IMT in different carotid segments should be treated as separate phenotypes.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

### Sources of Funding

This work was supported by grants from the National Institute of Neurological Disorders and Stroke R01 NS40807 (S.-H.H.J., T.R., R.L.S.), RO1 NS047655 (S.-H.H.J., T.R., R.L.S., R.C.), RO1 NS29993 (R.L.S., T.R.), the Irving General Clinical Research Center (2 M01 RR00645), and the National Health Research Institutes (Taiwan) NHRI-Ex96-9607 (S.-H.H.J., H.F.L., Y.-C.L.).

## References


1. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Engl J Med* 1999;340:14–22. [PubMed: 9878640]
2. Fox CS, Polak JF, Chazaro I, Cupples A, Wolf PA, D'Agostino RA, O'Donnell CJ. Genetic and environmental contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study. *Stroke* 2003;34:397–401. [PubMed: 12574549]
3. Humphries SE, Morgan L. Genetic risk factors for stroke and carotid atherosclerosis: Insights into pathophysiology from candidate gene approaches. *Lancet Neurol* 2004;3:227–235. [PubMed: 15039035]
4. Crouse JR, Goldbourt U, Evans G, Pinsky J, Sharrett AR, Sorlie P, Riley W, Heiss G. Risk factors and segment-specific carotid arterial enlargement in the Atherosclerosis Risk In Communities (ARIC) cohort. *Stroke* 1996;27:69–75. [PubMed: 8553406]

5. Schott LL, Wildman RP, Brockwell S, Simkin-Silverman LR, Kuller LH, Sutton-Tyrrell K. Segment-specific effects of cardiovascular risk factors on carotid artery intima-medial thickness in women at midlife. *Arterioscler Thromb Vasc Biol* 2004;24:1951–1956. [PubMed: 15297277]
6. Sacco RL, Anand K, Lee HS, Boden-Albala B, Stabler S, Allen R, Paik MC. Homocysteine and the risk of ischemic stroke in a triethnic cohort: the Northern Manhattan Study. *Stroke* 2004;35:2263–2269. [PubMed: 15345803]
7. Rodriguez CJ, Sciacca RR, Diez-Roux AV, Boden-Albala B, Sacco RL, Homma S, DiTullio MR. Relation between socioeconomic status, race–ethnicity, and left ventricular mass: the Northern Manhattan Study. *Hypertension* 2004;43:775–779. [PubMed: 14981073]
8. Rundek T, Elkind MS, Pittman J, Boden-Albala B, Martin S, Humphries SE, Juo SH, Sacco RL. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. *Stroke* 2002;33:1420–1423. [PubMed: 11988625]
9. Touboul PJ, Prati P, Scarabin PY, Adrai V, Thibout E, Ducimetiere P. Use of monitoring software to improve the measurement of carotid wall thickness by B-mode imaging. *J Hypertens Suppl* 1992;10:S37–S41. [PubMed: 1403232]
10. Shen R, Fan JB, Campbell D, Chang W, Chen J, Doucet D, Yeakley J, Bibikova M, Wickham Garcia E, McBride C, Steemers F, Garcia F, Kermani BG, Gunderson K, Oliphant A. High-throughput SNP genotyping on universal bead arrays. *Mutat Res* 2005;573:70–82. [PubMed: 15829238]
11. Juo SH, Rundek T, Lin HF, Cheng R, Lan MY, Huang JS, Boden-Albala B, Sacco RL. Heritability of carotid artery distensibility in Hispanics: the Northern Manhattan Family Study. *Stroke* 2005;36:2357–2361. [PubMed: 16224080]
12. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263–265. [PubMed: 15297300]
13. Tzeng JY, Wang CH, Kao JT, Hsiao CK. Regression-based association analysis with clustered haplotypes through use of genotypes. *Am J Hum Genet* 2006;78:231–242. [PubMed: 16365833]
14. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. *Atherosclerosis Risk In Communities study. Circulation* 1995;91:284–290. [PubMed: 7805229]
15. de Maat MP, Bladbjerg EM, Drivsholm T, Borch-Johnsen K, Moller L, Jespersen J. Inflammation, thrombosis and atherosclerosis: results of the Glostrup study. *J Thromb Haemost* 2003;1:950–957. [PubMed: 12871360]
16. Zwicker JJ, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, Mannucci P. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. *Blood* 2006;108:1280–1283. [PubMed: 16684956]
17. Roth JJ, Gahtan V, Brown JL, Gerhard C, Swami VK, Rothman VL, Tulenko TN, Tuszynski GP. Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. *J Surg Res* 1998;74:11–16. [PubMed: 9536966]
18. Narizhneva NV, Razorenova OV, Podrez EA, Chen J, Chandrasekharan UM, DiCorleto PE, Plow EF, Topol EJ, Byzova TV. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. *Faseb J* 2005;19:1158–1160. [PubMed: 15833768]
19. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). *J Exp Med* 1996;184:1101–1109. [PubMed: 9064327]
20. Koyama H, Maeno T, Fukumoto S, Shoji T, Yamane T, Yokoyama H, Emoto M, Shoji T, Tahara H, Inaba M, Hino M, Shioi A, Miki T, Nishizawa Y. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. *Circulation* 2003;108:524–529. [PubMed: 12860908]
21. Coll B, Alonso-Villaverde C, Parra S, Montero M, Tous M, Joven J, Masana L. The stromal derived factor-1 mutated allele (SDF1–3'A) is associated with a lower incidence of atherosclerosis in HIV-infected patients. *AIDS* 2005;19:1877–1883. [PubMed: 16227796]
22. Tsutsui M. Neuronal nitric oxide synthase as a novel anti-atherogenic factor. *J Atheroscler Thromb* 2004;11:41–48. [PubMed: 15153662]



23. Turner ST, Boerwinkle E. Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. *Pharmacogenomics* 2003;4:53–65. [PubMed: 12517286]
24. Sayed-Tabatabaei FA, Houwing-Duistermaat JJ, van Duijn CM, Witteman JC. Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. *Stroke* 2003;34:1634–1639. [PubMed: 12805498]
25. Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, Toyry J, Humphries SE. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. *Arterioscler Thromb Vasc Biol* 2000;20:2657–2662. [PubMed: 11116068]
26. Armstrong C, Abilleira S, Sitzer M, Markus HS, Bevan S. Polymorphisms in MMP family and TIMP genes and carotid artery intima-media thickness. *Stroke* 2007;38:2895–2899. [PubMed: 17901377]
27. Srinivasan SR, Li S, Chen W, Tang R, Bond MG, Boerwinkle E, Berenson GS. Q192R polymorphism of the paraoxonase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. The Bogalusa Heart Study. *Atherosclerosis* 2004;177:167–174. [PubMed: 15488880]
28. Karvonen J, Kauma H, Paivansalo M, Kesaniemi YA. Paraoxonase-1 gene Leu-Met55 and Gln-Arg192 polymorphisms are not associated with carotid artery atherosclerosis in a population-based cohort. *Eur J Cardiovasc Prev Rehabil* 2004;11:511–512. [PubMed: 15580063]
29. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. *Arterioscler Thromb Vasc Biol* 1998;18:1617–1624. [PubMed: 9763535]
30. Ranade K, Kirchgessner TG, Iakoubova OA, Devlin JJ, DelMonte T, Vishnupad P, Hui L, Tsuchihashi Z, Sacks FM, Sabatine MS, Braunwald E, White TJ, Shaw PM, Dracopoli NC. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. *Stroke* 2005;36:2346–2350. [PubMed: 16239632]
31. Orbe J, Beloqui O, Rodriguez JA, Belzunce MS, Roncal C, Paramo JA. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. *Clin Chim Acta* 2006;368:138–143. [PubMed: 16458279]
32. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Viridis A, Ciabattini G, Notarbartolo A, Cuccurullo F, Mezzetti A. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. *JAMA* 2004;291:2221–2228. [PubMed: 15138244]
33. Liang J, Liu E, Yu Y, Kitajima S, Koike T, Jin Y, Morimoto M, Hatakeyama K, Asada Y, Watanabe T, Sasaguri Y, Watanabe S, Fan J. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. *Circulation* 2006;113:1993–2001. [PubMed: 16636188]
34. Grainger DJ. TGF-beta and atherosclerosis in man. *Cardiovasc Res* 2007;74:213–222. [PubMed: 17382916]
35. Fox CS, Cupples LA, Chazaro I, Polak JF, Wolf PA, D'Agostino RB, Ordovas JM, O'Donnell CJ. Genomewide linkage analysis for internal carotid artery intimal medial thickness: evidence for linkage to chromosome 12. *Am J Hum Genet* 2004;74:253–261. [PubMed: 14730480]
36. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. *Proc Natl Acad Sci U S A* 1996;93:10417–10422. [PubMed: 8816815]
37. De Keulenaer GW, Chappell DC, Ishizaka N, Nerem RM, Alexander RW, Griendling KK. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase. *Circ Res* 1998;82:1094–1101. [PubMed: 9622162]
38. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. *JAMA* 1999;282:2035–2042. [PubMed: 10591386]

39. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. *Circulation* 2007;115:459 – 467. [PubMed: 17242284]



**Figure.** The relationship between the 3 GRS groups and CCA\_IMT and Bif\_IMT. IMT were adjusted for age, sex, body weight, HDL-C, and hypertension. The 3 GRS groups were defined based on mean $\pm$ 1 SD. The number of subjects in each GRS category is shown in parentheses.

**Table 1**  
Association Between Carotid IMT and Vascular Risk Factors (Univariate Regression Analysis)

Vascular Risk Factors	Mean±SD or Percent	Regression Coefficient $\beta \times 10^2$ (95% CI)		
		CCA_IMT	Bif_IMT	ICA_IMT
Age, years	64.5±7.4	0.25 (0.14–0.37)‡	0.12 (0.00–0.24)	0.02 (–0.07–0.12)
Male	45.3%	0.70 (–1.05–2.46)	2.80 (1.02–4.58)†	2.30 (0.92–3.68)†
Total cholesterol, mmol/L	5.14±0.96	0.57 (–0.33–1.47)	–0.83 (–1.75–0.10)	–0.16 (–0.89–0.56)
LDL-C, mmol/L	3.29±0.86	0.86 (–0.16–1.88)	–0.47 (–1.53–0.59)	0.20 (–0.62–1.03)
HDL-C, mmol/L	1.10±0.33	–1.24 (–3.85–1.38)	–3.09 (–5.79–0.39)*	–1.59 (–3.69–0.52)
Triglyceride, mmol/L	1.63±0.92	–0.00 (–0.94–0.94)	–0.35 (–1.32–0.63)	–0.30 (–1.06–0.46)
Weight, kg	74.2±13.5	0.03 (0.00–0.06)*	0.01 (–0.02–0.04)	0.01 (–0.01–0.03)
Diabetes	24.5%	1.56 (–0.47–3.59)	2.04 (–0.03–4.12)	1.43 (–0.19–3.04)
Hypertension	74.3%	2.93 (0.95–4.91)†	0.44 (–1.61–2.49)	–0.68 (–2.27–0.90)
Former smoker	37.3%	0.82 (–0.99–2.63)	1.25 (–0.60–3.10)	0.67 (–0.77–2.11)
Current smoker	14.0%	1.68 (–0.84–4.20)	0.65 (–1.94–3.23)	0.20 (–1.82–2.22)

\*  $P < 0.05$ .

†  $P < 0.01$ .

‡  $P < 0.001$ .

LDL-C indicates low-density lipoprotein cholesterol.

**Table 2**  
Association Between Carotid IMT and Significant Genes (Multivariate Regression Analysis)

Category	Gene Symbol, Official Name	SNP	Risk Genotype	$\beta$ (P)	
				CCA_IMT	Bif_IMT
Hemostasis	<i>PLAT</i> , tissue plasminogen activator	rs879293	AG, GG	0.044 (0.0005)	0.013 (0.323)
	<i>THBS1</i> , thrombospondin 1	rs2292305(Ala523Thr)	GG	0.054 (0.0037)	0.029 (0.147)
Extracellular matrix remodeling	<i>MMP12</i> , matrix metalloproteinase 12	rs11225442	AA	0.024 (0.336)	0.094 (0.0004)
	<i>MMP3</i> , matrix metalloproteinase 3	rs655403	AA	0.039 (0.441)	0.173 (0.0010)
	<i>TGF<math>\beta</math>2</i> , transforming growth factor beta 2	rs12097734	AG	0.009 (0.547)	0.048 (0.0014)
Endothelium function	<i>NOS1</i> , nitric oxide synthase 1	rs2293050	AG, GG	0.035 (0.0007)	0.009 (0.421)
Renin-angiotensin system	<i>SELP</i> , P-selectin	rs3766126	CC, AC	0.019 (0.0049)	0.006 (0.396)
	<i>SCNN1B</i> , sodium channel 1 beta	rs152740	AT, TT	0.027 (0.0039)	0.008 (0.419)
	<i>ACE</i> , angiotensin I converting enzyme	rs8066276	AG, GG	0.016 (0.112)	0.034 (0.0019)
Inflammation	<i>REN</i> , renin	rs1464816	AA, AC	0.011 (0.183)	0.026 (0.0037)
	<i>CXCL12</i> , chemokine (C-X-C motif) ligand 12	rs2297630	GG	0.026 (0.0043)	0.003 (0.707)
Antioxidation	<i>PTGS2</i> , prostaglandin-endoperoxide synthase 2	rs20417(G-765C)	GG	0.025 (0.237)	0.066 (0.0032)
	<i>PON1</i> , paraoxonase 1	rs662(Gln192Arg)	AG, GG	0.003 (0.671)	0.018 (0.0044)

**Table 3**The Phenotype Variation ( $R^2$ ) and Effect Size ( $\beta$ ) of Covariates and Gene Risk Score

Covariates *	CCA_IMT		Bif_IMT	
	$\beta$	<i>P</i>	$\beta$	<i>P</i>
Age $\times$ 5 years	0.014	$1.6 \times 10^{-6}$	0.008	0.010
Male sex	0.000	NS	0.021	0.024
Weight $\times$ 5 kg	0.003	0.028	0.001	NS
HDL-C $\times$ 0.13 mmol/L	-0.001	NS	-0.003	NS
Hypertension	0.013	NS	-0.006	NS
GRS	0.015	Nominal $P=2.3 \times 10^{-9}$ empirical $P=2 \times 10^{-6}$	0.014	Nominal $P=7.2 \times 10^{-8}$ empirical $P=2 \times 10^{-6}$
	$R^2_{\text{gene}}=8.9\%$ , $R^2_{\text{covariate}}=7.5\%$		$R^2_{\text{gene}}=7.2\%$ , $R^2_{\text{covariate}}=4.1\%$	

\* Only covariates significantly associated with IMT in the univariate regression are included. NS indicates  $P \geq 0.05$ .